Arteriosclerosis
Not yet recruitingA study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.
A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.
- Disease:Arteriosclerosis
- Substances:Muvalaplin
Germany- Participants:18–64 years · 65+ years
- Substances:Muvalaplin
- Sponsor:Eli Lilly & Co.










